Cognetivity Neurosciences Ltd. (CGNSF) Stock
Cognetivity Neurosciences Ltd. is a healthcare firm focused on advanced cognitive assessment.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Cognetivity Neurosciences Ltd.
Cognetivity Neurosciences Ltd. is a healthcare firm focused on advanced cognitive assessment. The company has developed a sophisticated platform for cognitive testing, designed for use across diverse settings including medical facilities, commercial environments, and by individual consumers. This innovative system's primary goal is to identify the very first signs of cognitive impairment through a comprehensive evaluation of broad brain functions, thereby assisting in the diagnosis of conditions like dementia. In addition to its core platform, Cognetivity also provides OptiMind, a dedicated wellness application. Established in 2015, the company initially operated under the name Utor Capital Corp. before officially rebranding to Cognetivity Neurosciences Ltd. in December 2017. Its main offices are situated in Vancouver, Canada.
Cognetivity Neurosciences Ltd. (CGNSF) stock trades at $0.00 with a market capitalization of $8959. The stock is valued at a price-to-earnings (P/E) ratio of -0.12, price-to-book of -0.10, price-to-sales of 0.09. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.
On profitability, Cognetivity Neurosciences Ltd. generates a return on equity (ROE) of 70.00% — well above the market average, a sign of a high-quality business, return on capital employed of 82.30%, an operating margin of -3033.40%, a net profit margin of 0.00%.
Official website: www.cognetivity.com